Plain-English translation of NCT06749860 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing whether disitamab vedotin, when combined with two other medications called tislelizumab and bevacizumab, can effectively treat people with advanced or metastatic non-small cell lung cancer that has HER2 mutations or changes. The study includes people who have never been treated before and those who have already tried other treatments. Researchers want to see how well this three-drug combination works and how long patients survive without their cancer getting worse.
Many patients with advanced lung cancer need better treatment options, especially those with specific HER2 changes in their cancer cells. This medication is designed to target HER2, and when combined with two other drugs that boost the immune system and block blood vessel growth, researchers believe it may work better than current treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination treatment on a regular schedule, likely through intravenous infusions or injections at a hospital or clinic. You would have regular follow-up visits to check your health, get blood tests, and have scans to see how your cancer is responding. The study will track how well the treatment works, how long you survive, and what side effects you experience. Your participation would continue until your cancer stops responding to treatment or side effects become too difficult to manage.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China